Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Nangibotide (Primary)
  • Indications Septic shock
  • Focus Adverse reactions
  • Sponsors Inotrem
  • Most Recent Events

    • 30 Sep 2018 Results presented in an Inotrem media release.
    • 30 Sep 2018 According to an Inotrem media release, data from this study were presented at the annual congress of the International Sepsis Forum.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top